Revvity, Inc
—- Market cap
- —
- Debt
- +$3.22B
- Cash
- −$919.86M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: RVTY stock price vs VTRS: inconclusive — current versus $34.29 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VTRS's multiple
Implied fair value · at RVTY's multiple
Needs RVTY P/S.
Snapshot Sep 8, 2026, 2:28 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RVTY FY 2025 (ended Dec 28, 2025) · VTRS FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 57% equity / 43% debt · EV / Revenue 2.26x · EV / EBITDA 1383.97x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REVVITY, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
VIATRIS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.44x
0.98x
Net debt / EBITDA
Leverage against operating earnings
3.02x
561.72x
Cash and equivalents
Liquid reserves on the balance sheet
$919.86M
$1.32B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AGILENT TECHNOLOGIES, INC.
RVTY vs A
WATERS CORP /DE/
RVTY vs WAT
BIO-RAD LABORATORIES, INC.
RVTY vs BIO
METTLER TOLEDO INTERNATIONAL INC/
RVTY vs MTD
DANAHER CORP /DE/
RVTY vs DHR
THERMO FISHER SCIENTIFIC INC.
RVTY vs TMO
PFIZER INC
RVTY vs PFE
Organon & Co.
RVTY vs OGN
BRISTOL MYERS SQUIBB CO
RVTY vs BMY
AbbVie Inc.
RVTY vs ABBV
Merck & Co., Inc.
RVTY vs MRK
$3.22B
$14.41B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.